分泌型磷脂酶A2-ⅡA致病作用及其抑制剂的研究进展

张伟,谌娟,宋磊,叶龙

中国药学杂志 ›› 2016, Vol. 51 ›› Issue (6) : 429-432.

PDF(666 KB)
PDF(666 KB)
中国药学杂志 ›› 2016, Vol. 51 ›› Issue (6) : 429-432. DOI: 10.11669/cpj.2016.06.001
综 述

分泌型磷脂酶A2-ⅡA致病作用及其抑制剂的研究进展

  • 张伟,谌娟,宋磊,叶龙*
作者信息 +

An Overview on the Pathogenesis of sPLA2-ⅡA and Related Drug Development

  • ZHANG Wei,CHEN Juan,SONG Lei,YE Long*
Author information +
文章历史 +

摘要

分泌型磷脂酶A2-ⅡA (secretory phospholipase A2 group ⅡA,sPLA2-ⅡA)属于磷脂酶家族的一种小分子酶类。近年来有关该酶在心血管、肿瘤和自身免疫疾病中的作用多有报道,以其为靶点的相关实验药物也不断出现,因此分泌型磷脂酶A2-ⅡA在上述相关疾病的药物研发中愈来愈受到重视。笔者重点简要介绍分泌型磷脂酶A2-ⅡA的结构特点、近期对其在机体内的致病作用的研究和以其为靶点的药物研发现状。

Abstract

Secretory phospholipase A2 group ⅡA is an enzyme that hydrolyzes the sn-2 ester in glyceroacyl phospholipids present in lipoproteins and cell membranes. There have been an increasing number of reports regarding the pathogenesis of the enzyme in cardiovascular,tumor and autoimmune diseases in recent years and drug development targeting the enzyme is receiving more and more attention as a result. This article reviews research RESULTS in the above areas and current status of drug development based on reported sPLA2-II inhibitors.

关键词

分泌型磷脂酶A2-ⅡA / 结构 / 发病机制 / 抑制剂 / 作用机制

Key words

secretory phospholipase A2 group ⅡA / structural feature / pathogenesis / inhibitor / mechanism of action

引用本文

导出引用
张伟,谌娟,宋磊,叶龙. 分泌型磷脂酶A2-ⅡA致病作用及其抑制剂的研究进展[J]. 中国药学杂志, 2016, 51(6): 429-432 https://doi.org/10.11669/cpj.2016.06.001
ZHANG Wei,CHEN Juan,SONG Lei,YE Long. An Overview on the Pathogenesis of sPLA2-ⅡA and Related Drug Development[J]. Chinese Pharmaceutical Journal, 2016, 51(6): 429-432 https://doi.org/10.11669/cpj.2016.06.001
中图分类号: R965   

参考文献

[1] ZHANG X,WANG J J. Phospholipase A2 and cancer[J]. Int J Oncol,2011,38(12):897-900.
[2] GULI N E. Secretory phospholipase A2 type characteristics and clinical application[J]. Lab Med Clin
(检验医学与临床),2014,11(16): 2311-2312.
[3] XIE H F,LI K,NI Y. PLA2 Subtypes and their relationships with male reproduction[J]. Chin J Cell Biol(中国细胞生物学学报),2013,35( 1) :71-78.
[4] MYRAKAMI M,TAKETOMI Y,MIKI Y,et al.Recent progress in phospholipaseA2 research: from cells to animals to humans[J]. Prog Lipid Res
,2011,50( 2) : 152-192.
[5] DAN P,ROSENBLAT G,YEDGAR S. Phospholipase A2 activities in skin physiology and pathology[J]. Eur J Pharmacol,2012,691(1-3) : 1-8.
[6] MURAKAMI M,TAKETOMI Y,GIRARD C,et al.Emerging roles of secreted phospholipase A2 enzymes: lessons from transgenic and knock out mice[J]. Biochimie
,2010,92(6) :561-582.
[7] NIESSEN H W,KRIJNEN P A,VISSER C A,et al.Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes ? [J].Cardiovasc Res,2003,60(1) : 68-77.
[8] YU J A,KALATARDI S,DOHSE J,et al.Group IIa sPLA2 inhibition attenuates NF-κB activity and promotes apoptosis of lung cancer cells[J]. Anticancer Res,2012,32(9):3601-3607.
[9] LONG Y,TIFFANG D,HANDEEP K,et al
.Identification of inhibitors against interaction between pro-inflammatory sPLA2-IIA protein and integrin αvβ3 [J]. Bioorg Med Chem Lett,2013,23(1) :340-345.
[10] FUJITA M,ZHU K,FUJITA C K,et al.Proinflammatory secreted phospholipase A2 type IIA(sPLA-IIA) induces integrin activation through direct binding to a newly identified binding site (site 2) in integrins αvβ3,α4β1 and α5β1[J]. J Biol Chem
,2015,290(1):259-271.
[11] MAKOTO M,YOSHITAKA T,YOSHIMI M,et al.Recent progress in phospholipase A2 research: From cells to animals to humans[J]. Prog Lipid Res,2011,50(2):152-192.
[12] PETER L,PAUL M R,GORAN K H,et al.Inflammation in atherosclerosis [J]. JACC
,2009,54(23) : 2329-2338.
[13] LIU Z Z,DONG B,LIU T B,et al.Effects of ramipril on expression of lectin-like oxidized low density lipoprotein receptor-1 in rabbit model of atherosclerosis[J]. Chin J Arterioscler(中国动脉硬化杂志),2006,14(1) : 37-40.
[14] ZHOU X P,GAO Y D. sPLA2-IIA and cardiovascular disease[J]. Chin J Arteriosclerosis
(中国动脉硬化杂志),2005,13(2):239-241.
[15] ZHONG Y D,JAROSLAW M,PAUL S,et al.Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells[J]. Int J Oncol,2014,45(3): 978-984.
[16] LESLIE O,YIN L,BRUCE B,et al.Secretory phospholipaseA2-IIa is a Target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosisof prostate cancer[J]. The Prostate
,2012,72(10):1140-1149.
[17] CAI Q,ZHAO Z,ANTALIS C,et al.Elevated and secreted phospholipase A activities as new potential therapeutic targets in human epithelial ovarian cancer[J]. FASEB J,2012,26(8): 3306-3320.
[18] ZHANG Y,JIANG K,WANG C Y,et al.Pancreatic cancer patients serum level of sPLA2-IIa and its relationship with prognosis[J]. Chin J Dig(
中华消化杂志),2014,34(5):340-341.
[19] MATIN R,HERNANDEZ M,IBEAS E,et al.Secreted phospholipase A2-IIA modulated key regulators of proliferation on astrocytoma cells[J]. Neurochem,2009,111(4):988-999.
[20] JUN S,NOBUAKI A,CHUN Y W,et al.Pro-inflammatory secretory phospholipase A2 type IIa binds to integrins αvβ 3 and α4β1 and induces proliferation of monocytic cells in an integrin-dependent manner[J]. Bio Chem
,2008,283(38):26107-26115.
[21] ZHANG X Y,ZHENG W W,HU J P. The expression and significance of IIA sPLA2 and TFF3 in gastric carcinoma and Precancerous lesions[J]. Mod Chin Doctor(中国现代医生) ,2012,50(18) : 120-122.
[22] CHEN H,WANG C D,ZHUANG Z H,et al.Expression of group-IIA secretory phospholipase A2 in gastric carcinoma and relationship to microvessel formation[J]. Fujian Med J(
福建医药杂志),2011,33(1):66-68.
[23] KUMARESAN G,TATIANA I,YONG H W,et al.Inhibition of gastric cancer invasion and metastasis by PLA2G2A,a novel b-catenin/TCF target gene[J]. Cancer Res,2008,68(11): 4277-4286.
[24] LEUNG S Y,CHEN X,CHU K M,et al.Botstein D and Brown PO: Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis[J]. Proc Natl Acad Sci USA
,2002,99:16203-16208.
[25] PAPANIKOLSOU A,WANG Q S ,MULHERKAR R,et al.Expression analysis of the group IIA secretory phospholipase A2 in mice with differential susceptibility to azoxymethane-induced colon tumorigenesis[J]. Carcinogensis,2000,21(2):133-138.
[26] TAN L L,LIAN N S,ZHANG L. The level of type IIA phospholipase A2 mRNA in coiorectal carciloma and its significance[J]. Chin J Oncol Prev and Treat(
中国癌症防治杂志),2011,3(1): 39-42.
[27] TRIBLER L,JENSEN L T,JORGENSEN K,et al. Increased expression and activity of group IIA and X secretory phospholipase A2 in peritumoral versus central colon carcinoma tissue[J]. Anticancer Res,2007,27(5A): 3179-3185.
[28] FIJNEMAN R J,PEHAM J R,CORMIER R T,et al.Expression of Pla2g2a prevents carcinogenesis in Muc2-deficient mice[J]. Cancer Sci November
,2008,99 (11): 2113-2119.
[29] CHEN L,ZOU X. Progress in global research and development of cardiovascular medicines[J]. Chin J New Drugs(中国新药杂志),2010,19(1):8-16.
[30] MA Q X,CHEN L M,WANG Y P. Pharmacody recent advances of a lipoprptein-associated phospholipases A2 specific inhibitor darapladib[J]. Chin Pharm J
(中国药学杂志),2015,50(4):317-322.
[31] GERARD L,MICHAEL H G. Biochemistry and physiology of mammalian secreted phospholipases A2[J]. Annu Rev Biochem,2008,77:495-520. doi: 10. 1146/annurev. biochem. 76. 062405. 154007.
[32] KITSIOULI E,ANTONIOU G,GOTZOU H,et al. Effect of azithromycin on the LPS-induced production and secretion of phospholipase A2 in lung cells[J]. Biochim Biophys Acta
,2015,1852(7):1288-1297. doi: 10. 1016/j. bbadis. 2015. 03. 008.
[33] KU S K,LEE H G,BAE J S. Inhibitory effect of baicalin,baicalein and wogonin on secretory group IIA phospholipase A2[J]. Arch Pharm Res,2015,38(10):1865-1872.
[34] YU J,KALATARDI S,DOHSE J,et al.Group IIa sPLA2 inhibition attenuates NF-κB activity and promotes apoptosis of lung cancer cells[J]. Anticancer Res
,2012,32(9):3601-3608.

基金

湖北省自然科学基金资助项目(2015CFB490)
PDF(666 KB)

Accesses

Citation

Detail

段落导航
相关文章

/